Log in

NASDAQ:APLTApplied Therapeutics Stock Price, Forecast & News

+0.56 (+1.17 %)
(As of 05/26/2020 04:00 PM ET)
Today's Range
Now: $48.29
50-Day Range
MA: $42.03
52-Week Range
Now: $48.29
Volume118,705 shs
Average Volume161,211 shs
Market Capitalization$1.06 billion
P/E RatioN/A
Dividend YieldN/A
Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy. The company's preclinical stage products include AT-001 for acute myocardial infraction; AT-007 for treating galactosemia; AT-003 to treat diabetic retinopathy; and AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.18 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:APLT



Sales & Book Value

Annual SalesN/A



Market Cap$1.06 billion
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive APLT News and Ratings via Email

Sign-up to receive the latest news and ratings for APLT and its competitors with MarketBeat's FREE daily newsletter.

Applied Therapeutics (NASDAQ:APLT) Frequently Asked Questions

How has Applied Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Applied Therapeutics' stock was trading at $29.59 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, APLT stock has increased by 63.2% and is now trading at $48.29. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Applied Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Applied Therapeutics.

When is Applied Therapeutics' next earnings date?

Applied Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Applied Therapeutics.

How were Applied Therapeutics' earnings last quarter?

Applied Therapeutics (NASDAQ:APLT) released its earnings results on Monday, May, 11th. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.82) by $0.23. View Applied Therapeutics' earnings history.

What price target have analysts set for APLT?

6 analysts have issued twelve-month price objectives for Applied Therapeutics' shares. Their forecasts range from $43.00 to $65.00. On average, they expect Applied Therapeutics' share price to reach $55.20 in the next year. This suggests a possible upside of 14.3% from the stock's current price. View analysts' price targets for Applied Therapeutics.

Has Applied Therapeutics been receiving favorable news coverage?

News headlines about APLT stock have trended extremely positive on Wednesday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Applied Therapeutics earned a news impact score of 5.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutApplied Therapeutics.

Are investors shorting Applied Therapeutics?

Applied Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 642,100 shares, an increase of 56.8% from the April 30th total of 409,500 shares. Based on an average daily volume of 196,400 shares, the short-interest ratio is presently 3.3 days. Currently, 5.1% of the company's stock are short sold. View Applied Therapeutics' Current Options Chain.

Who are some of Applied Therapeutics' key competitors?

What other stocks do shareholders of Applied Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Therapeutics investors own include Vertex Pharmaceuticals (VRTX), Alteryx (AYX), Enterprise Products Partners (EPD), Adobe (ADBE), Medtronic (MDT), Pfizer (PFE), Verizon Communications (VZ), Advanced Micro Devices (AMD), IBM (IBM) and Netflix (NFLX).

Who are Applied Therapeutics' key executives?

Applied Therapeutics' management team includes the following people:
  • Dr. Shoshana Shendelman Ph.D., Chairman, Founder, Pres, CEO & Sec. (Age 40)
  • Dr. Mark Joseph Vignola, Chief Financial Officer (Age 42)
  • Dr. Riccardo Perfetti, Chief Medical Officer (Age 59)

When did Applied Therapeutics IPO?

(APLT) raised $60 million in an initial public offering (IPO) on the week of May 13th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank served as the underwriters for the IPO and Baird was co-manager.

What is Applied Therapeutics' stock symbol?

Applied Therapeutics trades on the NASDAQ under the ticker symbol "APLT."

Who are Applied Therapeutics' major shareholders?

Applied Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Orbimed Advisors LLC (6.01%), Rock Springs Capital Management LP (3.85%), Driehaus Capital Management LLC (2.69%), BlackRock Inc. (2.42%), Franklin Resources Inc. (1.55%) and Emerald Advisers LLC (1.41%). Company insiders that own Applied Therapeutics stock include Joel S Marcus, Real Estate Equitie Alexandria, Shoshana Shendelman and Stacy J Kanter. View institutional ownership trends for Applied Therapeutics.

Which institutional investors are selling Applied Therapeutics stock?

APLT stock was sold by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, Federated Hermes Inc., Oppenheimer & Co. Inc., Morgan Stanley, JPMorgan Chase & Co., and UBS Group AG. View insider buying and selling activity for Applied Therapeutics.

Which institutional investors are buying Applied Therapeutics stock?

APLT stock was purchased by a variety of institutional investors in the last quarter, including Rock Springs Capital Management LP, Driehaus Capital Management LLC, Franklin Resources Inc., Orbimed Advisors LLC, Emerald Advisers LLC, BlackRock Inc., Invesco Ltd., and Sphera Funds Management LTD.. Company insiders that have bought Applied Therapeutics stock in the last two years include Joel S Marcus, Real Estate Equitie Alexandria, Shoshana Shendelman, and Stacy J Kanter. View insider buying and selling activity for Applied Therapeutics.

How do I buy shares of Applied Therapeutics?

Shares of APLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Applied Therapeutics' stock price today?

One share of APLT stock can currently be purchased for approximately $48.29.

How big of a company is Applied Therapeutics?

Applied Therapeutics has a market capitalization of $1.06 billion. Applied Therapeutics employs 4 workers across the globe.

What is Applied Therapeutics' official website?

The official website for Applied Therapeutics is www.appliedtherapeutics.com.

How can I contact Applied Therapeutics?

Applied Therapeutics' mailing address is 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173. The company can be reached via phone at 212-220-9226 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.